XML 88 R41.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY (DEFICIT) (Tables)
 12 Months Ended
Nov. 30, 2020
Equity [Abstract]  
Schedule of assumptions used for warrants

The assumptions that the Company used to determine the grant-date fair value of warrants granted for the years ended November 30, 2020 and 2019 were as follows:

     2020  2019
  Risk free rate   0.35 – 1.57%    1.69 – 3.05% 
  Expected dividends   0%   0%
  Expected volatility   98.28 – 109.93%    150 – 159% 
  Expected life   3.54 – 3.77 years    4.35 – 5 years 
  Market price of the Company's common stock on date of grant  $0.25    $0.14 – 0.16 
  Exercise price  $0.25   $0.25 

 
Schedule of warrants activity

The following table summarizes warrant activity, which includes the incentive warrants, for the year ended November 30, 2020:

 

      Number of
Warrants		     Weighted-Average
Exercise
Price
$		  
               
Outstanding, November 30, 2018       26,041,160       0.19  
Granted       22,223,058       0.25  
Expired       (2,476,999 )     (0.16 )
Outstanding, November 30, 2019       45,787,219       0.22  
Granted       2,146,836       0.25  
Exercised       (42,076,668 )     (0.21 )
Outstanding, November 30, 2020       5,857,386       0.24  
                   
Exercisable, November 30, 2020       5,857,386       0.24  
Exercisable. November 30, 2019       45,037,219       0.22
Schedule weighted-average remaining contract

The warrants outstanding at the end of the year had weighted-average remaining contract lives as follows:

 

    2020     2019  
      (years)       (years)  
Total outstanding warrants     2.82       3.55  
Total exercisable warrants     2.82       3.50